EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY 4.0

PET Ligands for Imaging Mutant Huntingtin Aggregates: A Case Study in Non‐For‐Profit Scientific Management

Catherine G F Dickmann iD, Selena Milicevic Sephton iD, Roger A Barker iD, Franklin I Aigbirhio iD

ChemBioChem · 2024

DOI: 10.1002/cbic.202400152 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift ChemBioChem, 2024. Verfasst von Catherine G F Dickmann und 3 weiteren Autor:innen. Beteiligte Einrichtung: Molecular Imaging Chemistry Laboratory, Wolfson Brain Imaging Centre, Department of Clinical Neurosciences, University of Cambridge, Cambridge, Unite…. Hauptthemen laut MEDLINE: Huntingtin Protein, Positron-Emission Tomography. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 53 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Positron emission tomography imaging of misfolded proteins with high‐affinity and selective radioligands has played a vital role in expanding our knowledge of neurodegenerative diseases such as Parkinson's and Alzheimer's disease. The pathogenesis of Huntington's disease, a CAG trinucleotide repeat disorder, is similarly linked to the presence of protein fibrils formed from mutant huntingtin (mHTT) protein. Development of mHTT fibril–specific radioligands has been limited by the lack of structural knowledge around mHTT and a dearth of available hit compounds for medicinal chemistry refinement. Over the past decade, the CHDI Foundation, a non‐for‐profit scientific management organisation has orchestrated a large‐scale screen of small molecules to identify high affinity ligands of mHTT, with lead compounds now reaching clinical maturity. Here we describe the mHTT radioligands developed to date and opportunities for further improvement of this radiotracer class.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Huntingtin ProteinPositron-Emission TomographyLigandsHumansProtein AggregatesMutationHuntington DiseaseRadiopharmaceuticals

Stichwörter der Autor:innen

Huntington's Diseasemutant huntingtinneurodegenerative disorderspositron emission tomographyproteinopathiesradiochemistryradiotracers

Substanzen

Huntingtin ProteinLigandsHTT protein, humanProtein AggregatesRadiopharmaceuticals

Autor:innen und Institutionen

  • Molecular Imaging Chemistry Laboratory, Wolfson Brain Imaging Centre, Department of Clinical Neurosciences, University of Cambridge, Cambridge, United Kingdom.
  • John van Geest Centre for Brain Repair, Department of Clinical Neurosciences, University of Cambridge, Cambridge, United Kingdom.

ORCID-Profile: Catherine G F Dickmann, Selena Milicevic Sephton, Roger A Barker, Franklin I Aigbirhio

Zitieren

APA

Dickmann, C. G. F., Milicevic Sephton, S., Barker, R. A., & Aigbirhio, F. I. (2024). PET Ligands for Imaging Mutant Huntingtin Aggregates: A Case Study in Non‐For‐Profit Scientific Management. ChemBioChem. https://doi.org/10.1002/cbic.202400152

Vancouver

Dickmann CGF, Milicevic Sephton S, Barker RA, Aigbirhio FI. PET Ligands for Imaging Mutant Huntingtin Aggregates: A Case Study in Non‐For‐Profit Scientific Management. ChemBioChem. 2024. doi:10.1002/cbic.202400152

BibTeX
@article{Dickmann2024,
  author = {Dickmann, Catherine G F and Milicevic Sephton, Selena and Barker, Roger A and Aigbirhio, Franklin I},
  title = {PET Ligands for Imaging Mutant Huntingtin Aggregates: A Case Study in Non‐For‐Profit Scientific Management},
  journal = {ChemBioChem},
  year = {2024},
  doi = {10.1002/cbic.202400152}
}
Kostenlos starten →